Genuine Biotech takes third shot at IPO as financial pressures mount
對賭協議壓頂之下 真實生物三闖港交所
Demand for the company’s core product has long since faded, and sales for the product took an additional hit after the termination of a distribution partnership with Fosun Pharma.
核心產品阿茲夫定市場需求早已消退，與復星醫藥合作終止導致營收斷崖式下滑，現金流瀕臨枯竭，還有一份僅剩7個月期限的上市對賭協議。